EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Advancing the use of Long‐Acting Extended Delivery formulations for HIV prevention in sub‐Saharan Africa: challenges, opportunities, and recommendations

Nyaradzo M Mgodi, Grant Murewanhema iD, Enos Moyo, Chesterfield Samba, Godfrey Musuka iD, Tafadzwa Dzinamarira, Joelle M Brown

Journal of the International AIDS Society · 2023

DOI: 10.1002/jia2.26115 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the International AIDS Society, 2023. Verfasst von Nyaradzo M Mgodi und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe. Hauptthemen laut MEDLINE: HIV Infections. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FIC NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The burden of HIV in sub‐Saharan Africa (SSA) remains unacceptably high, and disproportionately affects girls and women. While the introduction of oral HIV pre‐exposure prophylaxis (PrEP) in 2012 revolutionized HIV prevention, its effectiveness is dependent on user adherence and its implementation in SSA has faced numerous challenges. Patient‐level, interpersonal and structural barriers, including, for example, daily pill burden, side effects, lack of partner support, testing and disclosure, and costs have been found to reduce adherence to oral PrEP.

Discussion

Long‐acting extended delivery (LAED) formulations for PrEP, such as injectable long‐acting cabotegravir (CAB‐LA) and dapivirine vaginal ring (DPV‐VR) are critical additions to the HIV prevention toolkit and are especially important for populations such as adolescent girls and young women (AGYW) and other key populations who remain at significant risk of HIV acquisition while facing substantial barriers to preventive services. These LAED formulations have been shown to result in better adherence and fewer side effects, with CAB‐LA being superior to oral PrEP in reducing the risk of HIV acquisition. They can be used to overcome user burden and adherence challenges. However, the successful rollout of the DPV‐VR and CAB‐LA may be hampered by issues such as a shortage of healthcare providers (HCPs), inadequate parenteral medication infrastructure, increased workload for HCPs, patient concerns, the price of the medications and the possibility of drug resistance.

Conclusions

SSA must develop laboratory capabilities for monitoring patients on LAED formulations and enhance research on developing more non‐injectable LAED formulations. There is a need to train and retain more HCPs, implement task shifting, invest in healthcare infrastructure and integrate healthcare services. To reduce costs and improve availability, the region must advocate for patent license waivers for LAED formulations and procure drugs collectively as a region.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsAdolescentHumansFemaleDisclosureHealth FacilitiesHealth PersonnelAfrica South of the Sahara

Stichwörter der Autor:innen

AfricaPrEPadolescent girls and young womenlong-actingmen who have sex with menpreventionstigma

Autor:innen und Institutionen

  • University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
  • Unit of Obstetrics and Gynecology, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
  • Medical Centre, Oshakati, Namibia.
  • GALZ, Harare, Zimbabwe.
  • International Initiative for Impact Evaluation, Harare, Zimbabwe.
  • School of Health Systems and Public Health, University of Pretoria, Pretoria, 0084, South Africa.

ORCID-Profile: Grant Murewanhema, Godfrey Musuka

Förderung

  • FIC NIH HHS

Zitieren

APA

Mgodi, N. M., Murewanhema, G., Moyo, E., Samba, C., Musuka, G., Dzinamarira, T., & Brown, J. M. (2023). Advancing the use of Long‐Acting Extended Delivery formulations for HIV prevention in sub‐Saharan Africa: challenges, opportunities, and recommendations. Journal of the International AIDS Society. https://doi.org/10.1002/jia2.26115

Vancouver

Mgodi NM, Murewanhema G, Moyo E, Samba C, Musuka G, Dzinamarira T, et al. Advancing the use of Long‐Acting Extended Delivery formulations for HIV prevention in sub‐Saharan Africa: challenges, opportunities, and recommendations. Journal of the International AIDS Society. 2023. doi:10.1002/jia2.26115

BibTeX
@article{Mgodi2023,
  author = {Mgodi, Nyaradzo M and Murewanhema, Grant and Moyo, Enos and Samba, Chesterfield and Musuka, Godfrey and Dzinamarira, Tafadzwa and Brown, Joelle M},
  title = {Advancing the use of Long‐Acting Extended Delivery formulations for HIV prevention in sub‐Saharan Africa: challenges, opportunities, and recommendations},
  journal = {Journal of the International AIDS Society},
  year = {2023},
  doi = {10.1002/jia2.26115}
}
Kostenlos starten →